Year 2021 / Volume 113 / Number 5
Original
From Lauren’s diffuse gastric cancer to WHO’s poorly cohesive carcinoma. Clinicopathological and prognostic characteristics

324-331

DOI: 10.17235/reed.2020.7184/2020

Aingeru Sarriugarte Lasarte, Eva García Alberdi, Lorea Martínez Indart, Oihane Gutiérrez Grijalba, Irene Álvarez Abad, Mikel Guerra Lerma, Miguel Calle Baraja, Alberto Colina Alonso,

Abstract
Introduction: since Lauren classified gastric cancer into intestinal-type adenocarcinoma and diffuse gastric carcinoma back in 1965, countless categorizations have been published that attempt to elucidate the clinicopathological and prognostic differences between histological subtypes. Objective: a retrospective study was performed of gastric cancer cases managed in a third-level site over ten years in order to compare subtypes between the most widely used classifications (Lauren and World Health Organization [WHO]). Methods: a comparative study of the most relevant clinicopathological characteristics and a multivariate survival analysis were performed. Results: significant differences exist between histological subtypes in terms of age, gender, location, extension, stage and treatment received. A univariate overall survival analysis revealed better survival rates for intestinal-type adenocarcinoma as compared to diffuse carcinoma (hazard ratio [HR]: 1.405 [1.024-1.927]) according to the Lauren’s classification. Furthermore, there was a better prognosis of mucinous carcinoma (HR: 0.378 [0.164-0.868]), though failing to prove a poorer prognosis of poorly cohesive (HR: 1.242 [0.878-1.757]) and signet cell (HR: 1.354 [0.792-2.314]) carcinomas, according to the WHO classification. In the multivariate overall survival analysis, the following poor prognosis factors were identified: male gender, local infiltration (T), nodal invasion (N) and received adjuvant therapy. Conclusion: although the various histological subtypes show significant clinicopathological differences, further studies are needed to compare them and clarify the prognostic relevance of each one.
Share Button
New comment
Comments

05/07/2021 20:00:33
excelente y destacados casas de mucho interes para la especialidad ,gracias x compartir.Gabriel Cárdenas G Cali colombia u del valle, profesor asistente cirugia y Gastro quirurgico


08/06/2021 16:25:02
ESTOS HALLAZGOS DESCRITOS ,son los que evaluamos en nuestros pacientes ,considerando que el el adenoca bien diferenciado ,prima el reporte de la CACADA DE PELAYO e infeccion de HP+, y para los difusos estarian mas relacionados con el potencial genético, hereditario (exon 2 y 4?) ,cascada de CANEIRO en pacientes mas jovenes y comportamiento muy agresivo y mas si presenta cel, en anillo de sello y en los proximales el MARCADOR HER-2 para tto con biologicos?.
GRACIAS GABRIEL H CARDENAS G cirugia y endoscopia Digestiva -U DEL VALLE -CALI COLOMBIA
CC14877000 email fcardenas@calipso.com.co


References
1. Bray F et al. Globocan Ca Cancer J Clin 2018;68:394–424
2. Marrelli D, Pedrazzani C, Morgagni D, de Manzoni G, Pacelli F, Coniglio A, et al. Changing clinical and pathological features of gastric cancer over time. Bri J Surg. 2011;98:1273–83.
3. Slagter AE, Jansen EPM, van Laarhoven HWM, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18(1):877. Published 2018 Sep 10. doi:10.1186/s12885-018-4770-2
4. Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. World J Gastroenterol 2014; 20(19): 5679-5684. DOI: https://dx.doi.org/10.3748/wjg.v20.i19.5679
5. Marano L, D'Ignazio A, Cammillini F, et al. Comparison between 7th and 8th edition of AJCC TNM staging system for gastric cancer: old problems and new perspectives. Transl Gastroenterol Hepatol. 2019;4:22. Published 2019 Apr 3. doi:10.21037/tgh.2019.03.09
6. In, H., Solsky, I., Palis, B. et al. Ann Surg Oncol (2017) 24: 3683. https://doi.org/10.1245/s10434-017-6078-x
7. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 64:31-49, 1965.
8. U, B., El Hajj, N., Sittler, S., Lammert, N., Barnes, R., Meloni-Ehrig, A.. Gastric cancer: Classification, histology and application of molecular pathology. Journal of Gastrointestinal Oncology, North America, 3, jul. 2012.
9. Lauwers GY, Carneiro F, Graham DY, Curado M-P, Franceschi S, Montgomery E, Tatematsu M, Hattori T: Gastric Carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system, 4th ed. IARC Press: Lyon; 2010, pp. 48–58
10. Mariette, C. Carneiro, F., Grabsch, H.I. et al. Gastric Cancer (2019) 22: 1. https://doi.org/10.1007/s10120-018-0868-0
11. Serban D, Branescu C, et al. Complex histopathological and surgical aspects in a case of giant malignant gastric perforation. Journal of Medicine and Life Vol. 9, Issue 2, April-June 2016, pp.216-219
12. Zu H, Wang H, Li C, Xue Y. Clinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancer. Int J Clin Exp Pathol. 2014;7(9):5692–5700. Published 2014 Aug 15.
13. Qiu et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. Journal of Translational Medicine 2013, 11:58 http://www.translational-medicine.com/content/11/1/58
14. Cunningham D, M.D., William H. Allum, M.D., Sally P. Stenning et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine. 2006 Jul 6;355(1):11-20.
15. Al-Batran SE, Hofh einz RD, Pauligk C et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fl uorouracil, and leucovorin versus epirubicin, cisplatin, and fl uorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016; 17: 1697–708.
16. As Nie RC, Yuan SQ, Li YF, Chen YM, Chen XJ, Zhu BY, Xu LP, Zhou ZW, Chen S, Chen YB. Clinicopathological Characteristics and Prognostic Value of Signet Ring Cells in Gastric Carcinoma: A Meta-Analysis. J Cancer 2017; 8(17):3396-3404. doi:10.7150/jca.21017. Available from http://www.jcancer.org/v08p3396.htm
17. Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol 2015; 21(40): 11428-11438 Available from: URL: http://www.wjgnet. com/1007-9327/full/v21/i40/11428.htm DOI: http://dx.doi. org/10.3748/wjg.v21.i40.11428
18. C. Mariette, F. Carneiro, . I. Grabsch, et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer (2019) 22:1–9 https://doi.org/10.1007/s10120-018-0868-0
19. Tang X, Zhang J, Che X, Lan Z, Chen Y, Wang C. The clinicopathological features and long-term survival outcomes of mucinous gastric carcinoma: a consecutive series of 244 cases from a single institute. J Gastrointest Surg. 2016; 20:693-699
20. Bass, A. J., Thorsson, V., Shmulevich, I., et al, Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513(7517), 202-209. DOI: 10.1038/nature13480
21. IARC Publications. Digestive System Tumours. World Health Organization Classification of Tumours. 5th Edition. Chapter 3. Tumours of the stomach.
22. Birkman EM, Mansuri N, Kurki S, et al. Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics. Virchows Arch. 2018;472(3):369-382. doi:10.1007/s00428-017-2240-x
Citation tools
Sarriugarte Lasarte A, García Alberdi E, Martínez Indart L, Gutiérrez Grijalba O, Álvarez Abad I, Guerra Lerma M, et all. From Lauren’s diffuse gastric cancer to WHO’s poorly cohesive carcinoma. Clinicopathological and prognostic characteristics. 7184/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 4583 visits.
This article has been downloaded 683 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 24/04/2020

Accepted: 03/07/2020

Online First: 24/11/2020

Published: 10/05/2021

Article revision time: 64 days

Article Online First time: 214 days

Article editing time: 381 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology